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Background: Akt plays a major role in insulin regulation of metabolism.
Results: Akt operates at 5–22% of its dynamic range. This lacks concordance with Akt substrate phosphorylation, GLUT4
translocation, and protein synthesis.
Conclusion: Akt is a demultiplexer that splits the insulin signal into discrete outputs.
Significance: This study provides better understanding of the Akt pathway and has implications for the role of Akt in diseases.
Akt plays a major role in insulin regulation of metabolism in
muscle, fat, and liver. Here, we show that in 3T3-L1 adipocytes,
Akt operates optimally over a limited dynamic range. This indi-
cates thatAkt is a highly sensitive amplification step in the path-
way.With robust insulin stimulation, substantial changes inAkt
phosphorylation using either pharmacologic or genetic manip-
ulations had relatively little effect onAkt activity. By integrating
these data we observed that half-maximal Akt activity was
achieved at a threshold level of Akt phosphorylation corre-
sponding to 5–22% of its full dynamic range. This behavior was
also associated with lack of concordance or demultiplexing in
the behavior of downstream components. Most notably,
FoxO1 phosphorylation was more sensitive to insulin and did
not exhibit a change in its rate of phosphorylation between 1
and 100 nM insulin compared with other substrates (AS160,
TSC2, GSK3). Similar differences were observed between var-
ious insulin-regulated pathways such as GLUT4 transloca-
tion and protein synthesis. These data indicate that Akt itself
is a major amplification switch in the insulin signaling path-
way and that features of the pathway enable the insulin signal
to be split or demultiplexed into discrete outputs. This has
important implications for the role of this pathway in disease.
The protein kinase Akt, also known as protein kinase B
(PKB), is involved in many fundamental biological processes
including cell survival, proliferation, growth, and metabolism
(1, 2). In insulin-responsive tissues, activation of Akt involves
binding of insulin to the insulin receptor. This triggers the acti-
vation of its tyrosine kinase activity and results in its autophos-
phorylation and recruitment of scaffolding proteins such as
IRS1.3 Tyrosyl-phosphorylated IRS1 acts as a platform for the
assembly of a signaling node comprising among other proteins
the lipid kinase phosphatidylinositol 3-kinase (PI3K) leading to
the generation of phosphatidylinositol 3,4,5-trisphosphate
(PI(3,4,5)P3). This facilitates the translocation of Akt to the
plasma membrane (PM) where it is phosphorylated at Thr-308
and Ser-473 by phosphoinositide-dependent kinase 1 and
the mammalian target of rapamycin (mTOR) complex 2
(mTORC2), respectively (3, 4). Upon activation, Akt phosphor-
ylates a range of substrates such as glycogen synthase kinase 3
(GSK3), the Rab GTPase-activating protein (RabGAP) AS160,
also called TBC1D4, proline-rich Akt substrate of 40 kDa
(PRAS40), and RhebGAP tuberous sclerosis protein 2 (TSC2).
The phosphorylation of these substrates orchestrates a com-
plex metabolic program involving the translocation of the glu-
cose transporter GLUT4 to the PM leading to glucose uptake
into cells, increased glycogen and protein synthesis as well as
long term effects on transcription (5, 6).
The PI3K/Akt pathway is often portrayed as a linear cascade
whereby unitary changes in flux are transmitted equally
throughout the signaling network. However, this is likely to be
an oversimplification. First, insulin-responsive cells possess
“spare” receptors (7) whereby occupancy of a small number of
receptors is sufficient to achieve amaximal biological outcome.
This situation is thought to contribute to flexibility in terms of
the sensitivity and the intensity of insulin action. Second, the
Akt pathway possesses a number of feedback loops that atten-
uate transmission of the signal again adding to the nonlinearity
in this system. Most notably, mTOR as well as other down-
stream kinases such as S6 kinase, phosphorylate upstream ele-
ments in the Akt signaling pathway including IRS1 (8–11) or
Rictor (12), and this is often correlated with reduced Akt activ-
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important role in the development of insulin resistance, amajor
pathophysiological feature ofmetabolic disease. Third,many of
the components in this system such as Akt possess enzymatic
activity and so have the intrinsic capacity for signal amplifica-
tion. Fourth, several network components such as PI3K andAkt
comprise multiple isoforms displaying characteristically dis-
crete behavior (13–17). Finally, some of the network compo-
nents are subject to spatial regulation (14, 18), providing further
rationale for nonlinearity.
Here, we show that, as is the case for the insulin receptor, Akt
also exhibits nonlinear behavior such that the relationship
between Akt phosphorylation at its two major regulatory sites,
and downstream kinase activity is sigmoidal. Moreover, dis-
crete relationships between Akt phosphorylation and different
metabolic actions of insulin known to be downstream of Akt
were observed, suggesting that this single pathway is capable of
demultiplexing and splitting the upstream insulin signal into
discrete outputs. This has implications for the way that this
system operates in disease.
EXPERIMENTAL PROCEDURES
Materials and Antibodies—Polyclonal rabbit antibodies
pThr-308 Akt, pThr-1462 TSC2, pSer-21/9 GSK3/, pSer-
246 PRAS40, total PRAS40, and pThr-389 p70 S6 kinase,
monoclonal rabbit antibodies raised against total Akt (11E7),
Akt2 (D6G4), and total GSK3 (27C10), and monoclonal
mouse antibodies raised against pSer-473 Akt (587F11), Akt1
(2H10), and pTyrosines (pY100) were purchased fromCell Sig-
naling Technologies (Beverly, MA). Polyclonal rabbit antibody
raised against TSC2 and 14-3-3 was purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyclonal sheep
antibodies raised against pSer-588 AS160 and pThr-642 AS160
were obtained from Peter Shepherd (Symansis, Auckland, New
Zealand). Rabbit polyclonal antibodies against human AS160
were produced as described previously (19). Tubulin antibody
was from Sigma. Monoclonal anti-HA antibody was obtained
from Covance (Berkeley, CA). Horseradish peroxidase-conju-
gated secondary antibodies were from Amersham Biosciences,
and IRDye 700- or 800-conjugated secondary antibodies were
from Rockland Immunochemicals (Gilbertsville, PA). Parafor-
maldehyde was from ProSciTech (Thuringowa, Australia).
Dulbecco’s modified Eagle’s medium (DMEM) and newborn
calf serum were from Invitrogen. Fetal calf serum was from
Trace Scientific (Melbourne, Australia), and antibiotics were
from Invitrogen. Bovine serum albumin (BSA) was from Bovo-
gen (Essendon, Australia). Bicinchoninic acid reagent and
SuperSignal West Pico chemiluminescent substrate were from
Pierce. Protease inhibitor mixture tablets were from Roche
Applied Science. The Akt1-specific and Akt2-specific inhibi-
tors were previously described (20) and were obtained from
Merck. The Akt inhibitor, MK-2206, was generously provided
by Professor Dario Alessi (University of Dundee, Dundee, UK).
Other materials were obtained from Sigma.
Cell Culture—3T3-L1 fibroblasts (ATCC, Manassas, VA)
were cultured and differentiated to adipocytes as described pre-
viously (21). 3T3-L1 fibroblasts were infected with either pBa-
bepuro-HA-GLUT4 retrovirus only or together with pLXSN
PDGFR retrovirus. After a 24-h recovery period, infected cells
were selected with either 2 g/ml puromycin or together with
800 g/ml Geneticin in DMEM supplemented with 10% fetal
calf serum for selection of HA-GLUT4-infected cells or
HA-GLUT4/PDGFR-infected cells, respectively. Surviving
3T3-L1 fibroblasts were then grown to confluence and subse-
quently differentiated into adipocytes as described above.
Western Blot Analysis—Cells were washed twice with ice-
cold PBS and solubilized in 2% SDS in PBS containing phospha-
tase inhibitors (1 mM sodium pyrophosphate, 2 mM sodium
vanadate, 10 mM sodium fluoride) and complete protease
inhibitor mixture. Insoluble material was removed by centrifu-
gation at 18,000  g for 10 min. Protein concentration was
measured using the bicinchoninic acid method. Proteins were
separated by SDS-PAGE for immunoblot analysis. After trans-
ferring proteins to polyvinylidene difluoridemembranes,mem-
branes were incubated in blocking buffer containing 5% skim
milk in Tris-buffered saline and immunoblotted with the rele-
vant antibodies overnight at 4 °C in blocking buffer containing
5% BSA, 0.1% Tween in Tris-buffered saline. After incubation,
membranes were washed and incubated with horseradish per-
oxidase-labeled secondary antibodies and then detected by
SuperSignal West Pico chemiluminescent substrate. In some
cases, IRDye 700- or 800-conjugated secondary antibodieswere
used and then scanned at the 700 nm and 800 nm channel using
the Odyssey IR imager. Quantification of protein levels was
performed using Odyssey IR imaging system software or the
Wright Cell Imaging Facility ImageJ software.
Immunoprecipitation—Following the indicated treatment,
cells were washed with ice-cold PBS and solubilized in Nonidet
P-40 buffer (50 mm Tris-HCl, pH 7.5, 150 mm NaCl, 1% Non-
idet P-40, 1mmEDTA, and 10% glycerol) containing Complete
protease inhibitor mixture and phosphatase inhibitors (2 mm
sodium orthovanadate, 1 mm sodium pyrophosphate, 10 mm
sodium fluoride). Cell lysates were homogenized 10 times using
a 27-gauge needle and centrifuged at 18,000  g for 20 min at
4 °C.Onemgof cell lysateswas incubated overnight at 4 °Cwith
2 l of monoclonal mouse Akt1 antibody, monoclonal rabbit
Akt2, or nonimmunized rabbit or mouse IgG. Antibodies were
then captured with protein G-Sepharose beads for 2 h at 4 °C.
Immunoprecipitates were washed three times with ice-cold
Nonidet P-40 buffer and kept in 2  SDS sample buffer at
20 °C.
Quantitative GLUT4 Translocation Assay—HA-GLUT4
translocation to the PM was measured as described previously
(22). Briefly, 3T3-L1 adipocytes stably expressing PDGFR
and/or HA-GLUT4 in 96-well plates were serum-starved with
Krebs-Ringer phosphate buffer (0.6 mM Na2HPO4, 0.4 mM
NaH2PO4, 120 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1.2 mM
MgSO4, 12.5mMHEPES, pH 7.4) supplemented with 0.2% BSA
and with 20 nM rapamycin where indicated for 2 h. Cells were
then treated with dimethyl sulfoxide or the indicated com-
pound for 30 min prior to insulin stimulation for 20 min or as
indicated. After stimulation, cells were fixed and immunola-
beled with monoclonal anti-HA antibody followed by Alexa
Fluor 488-labeled secondary antibody in the absence or pres-
ence of saponin to analyze the amount ofHA-GLUT4 at the PM
or the total HA-GLUT4 content, respectively.
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Protein Synthesis Assay—3T3-L1 fibroblasts were seeded and
differentiated into adipocytes in 24-well plates. Cells were
washed twice and incubated with Krebs-Ringer phosphate
buffer supplemented with 0.2% BSA for 2 h prior to insulin
stimulation for 20 min. [3H]Leucine (PerkinElmer Life Sci-
ences) was added at the same time as insulin to a final concen-
tration of 5Ci/ml. To determine nonspecific leucine uptake, 5
Mcyclohexamidewas added for 1 h before addition of [3H]leu-
cine and insulin. Leucine incorporation was terminated with
three rapid washes in ice-cold PBS follow by incubating cells
with 10% trichloroacetic acid (TCA) for 10 min to precipitate
proteins. Pellets were washed three times in 10% TCA to
remove free [3H]leucine that was not incorporated. Pellets were
resuspended in 50 nMNaOHwith 1% Triton X-100 at 65 °C for
20 min. Samples were assessed for radioactivity by scintillation
counting using the -scintillation counter. The nonspecific
uptake was subtracted, and results were normalized for protein
content using BCA analysis. Each condition was performed in
triplicate.
Cationic Silica Isolation of Plasma Membrane—Plasma
membranes were purified as described (23) with some modifi-
cations. Briefly, after treatments, cells were washed twice with
ice-cold PBS and twice in ice-cold coating buffer (20 mM MES,
150mMNaCl, 280mM sorbitol, pH 5.0–5.5). Cationic silica in a
final concentration of 1% was added to the cells in coating
buffer for 2 min on ice. Cells were then washed with ice-cold
coating buffer to remove excess silica. Sodium polyacrylate (1
mg/ml, pH 6–6.5) was added to the cells in coating buffer and
incubated at 4 °C for 2 min. Cells were washed once in ice-cold
coating buffer and then washed with modified HES (20 mM
HEPES, 250mM sucrose, 1 mMDTT, 1mMmagnesium acetate,
100mMpotassium acetate, 0.5mM zinc chloride, pH 7.4) at 4 °C
and lysed as described above. Nycodenz (100%) in modified
HES buffer was added to the lysate to a final concentration of
50%. The lysate was layered onto 0.5 ml of 70% Nycodenz in
modifiedHES and centrifuged in a swing-out rotor at 25, 000
g for 20 min at 4 °C. The supernatant was discarded, and the
pellet was resuspended in 0.5 ml of modified HES buffer and
centrifuged at 500 g for 5 min at 4 °C. The pellet was resus-
pended in SDS-PAGE sample buffer and heated to 65 °C for 10
min.
siRNA Knockdown of Akt2—3T3-L1 cells at 6–7 days after
differentiation were detached using 5  trypsin/EDTA and
washed in DMEM/10% FCS medium containing 4% glycerol.
For each reaction, 2 million cells were resuspended in buffer L
(Amaxa Cell Line Nucleofector Kit L) containing siRNA at the
indicated concentrations. Following electroporation (Amaxa
Nucleofector II), cells were resuspended in 2ml of DMEM/10%
FCS and reseeded into 4 24-well plates and incubated for 72 h
at 37 °C before performing various experiments.
Data Analysis—The data from the experiments were quanti-
fied and normalized relative to the response when stimulating
3T3-L1 adipocytes with 100 nM insulin for 20 min. Basal values
were subtracted for the fitting of the data. Scaled data from all
experiments were combined as a single data set and fitted to a
logistic curve,
y  a  b  a)(110∧((LogED50 x)) (Eq. 1)
using GraphPad Prism, where a is the level at dose zero, which
was constrained to zero; b is the level at infinite dose; ED50 is the
dose at which half-maximal response is observed; and x is the
dose. Data are expressed as indicated in the figure legends. p
values were calculated by one-way or two-way ANOVA using
GraphPad Prism. Three-dimensional surface charts were cre-
ated inMicrosoft Excel wheremissing valueswere interpolated.
Computational PredictionUsingCellworksVirtualAdipocyte
Platform—Predictive experiments were performed using the
Virtual Adipocyte technology built upon an algorithm reported
previously (24–26). Briefly, the Cellworks Adipocyte Platform
was engineered based on an extensive literature search with
each individual process built as a stand-alone module. In the
case of inconsistent or unknown enzyme kinetic parameters, a
trial-and-error method of optimization was employed to attain
physiological outcome. Modules were tested individually for
correctness, and predictive values were corroborated with
experimental data. The Virtual Adipocyte Platform was stabi-
lized and fixed on control values corresponding to basal condi-
tion with 5 mM extracellular glucose concentration. This stabi-
lized system was transitioned into an insulin-stimulated
condition. Reduction of Thr-308 Akt1 and/or Akt2 phosphor-
ylation and knockdown ofAkt1 and/orAkt2 protein levels were
performed.
RESULTS
Inhibition of mTOR Increases Insulin-stimulated Phosphory-
lation of Akt with Minimal Effect on GLUT4 Translocation—A
major goal of this studywas to explore the relationship between
individual components within the insulin signaling network,
with a particular emphasis on Akt. We have previously shown
that a small degree of Akt phosphorylation is sufficient to
achieve a maximal biological outcome under normal biological
circumstances (27, 28). We reasoned that in view of this non-
linearity, changes in the amount of Akt phosphorylation might
not be translated into equivalent changes inAkt substrate phos-
phorylation. To explore this, we first examined the effects of
rapamycin on signaling because it has been shown to override a
negative feedback loop that attenuates Akt phosphorylation (6,
9, 11). 3T3-L1 adipocytes expressingHA-GLUT4were exposed
to insulin for 10–60min in the absence or presence of rapamy-
cin. Expression of HA-GLUT4 in 3T3-L1 adipocytes does not
alter insulin-dependent activation of the Akt signaling pathway
or the -fold response to insulin for glucose uptake (supplemen-
tal Fig. S1). Consistent with previous studies (9, 11), rapamycin
potentiated insulin-stimulated Akt phosphorylation at both
Thr-308 and Ser-473 by2-fold (Fig. 1, A and B).
To determine whether this effect was mediated via IRS1, we
examined the effects of rapamycin on PDGF-stimulated Akt
activation in 3T3-L1 adipocytes stably expressing the PDGF
receptors because this occurs independently of IRS1 (27). If the
mTORC1/S6 kinase negative feedback loop operates at the
level of IRS1, one would expect that rapamycin treatment
would not have an effect on PDGF-stimulated Akt phosphory-
lation. However, we observed a significant potentiation of Akt
phosphorylation in PDGF-stimulated cells when cells were
treatedwithrapamycin.Theextentof increase inAktphosphor-
ylation was similar to that observed in insulin-stimulated cells
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(Fig. 1, A–C). These data indicate that the rapamycin-sensitive
feedback inhibitory pathway that modulates Akt phosphoryla-
tion in 3T3-L1 adipocytes is unlikely to be IRS1-dependent.
The potentiation in insulin and PDGF-stimulated Akt acti-
vation was not accompanied by a significant change in regu-
lated phosphorylation of Thr-642 AS160 or Ser-9 GSK3, and
therewas a relativelyminor increase inGLUT4 translocation to
the PM in the presence of rapamycin (Fig. 1, A–D). When the
time course curves were integrated, only Akt phosphorylation
atThr-308 andSer-473 showed a significant increasewith rapa-
mycin treatment (Fig. 1E). These data indicate that the
mTORC1 negative feedback loop operates in adipocytes, and
this pathway plays a significant role in attenuating Akt phos-
phorylation acutely. However, this feedback mechanism does
not play a universal role in all Akt-dependent actions.
Acute Inhibition of Akt Phosphorylation Using Small Mole-
cule Inhibitors—To explore the nonlinearity at the Akt node
further, we next studied the effect of pharmacological inhibi-
tion of Akt with regard to its downstream activity. Tomodulate
the activity of Akt phosphorylation, we made use of isoform-
specific inhibitors of Akt (Akti). These inhibitors, Akt1i and
Akt2i, specifically inhibit Akt1 and Akt2, respectively, by bind-
ing to the PH domain, preventing the interaction of Akt with
the PM (20). We have previously documented the effects of
these inhibitors on Akt1 and Akt2 activity and have also
described a nonspecific effect on the transport activity of the
glucose transporter. Therefore, in these studies we focused our
analysis on GLUT4 translocation to the PM to avoid this prob-
lem (29). To determine the specificity of Akt1i and Akt2i,
3T3-L1 adipocytes were treated with insulin in the presence of
various doses of each inhibitor. Akt1 and Akt2 were immuno-
precipitated from cell lysates using isoform-specific antibodies
(Fig. 2A). At the lowest dose (10 M), each inhibitor exhibited
significant specificity with respect to its ability to inhibit phos-
phorylation of either Akt1 or Akt2, particularly at the Thr-308
site. This was not the case at higher doses (50–100 M) (Fig.
2A). These data indicate that these inhibitors achieve consider-
able isoform specificity at a concentration of 10 M.
We next determined the effects of these inhibitors on Akt
activity in 3T3-L1 adipocytes. At the lowest dose (10 M) of
each inhibitor, where they exhibited the highest specificity, we
observed a more significant inhibitory effect with Akt2i on Akt
phosphorylation. Simultaneous addition of both Akt1i and
Akt2i at 10 M resulted in inhibition of Thr-308 and Ser-473
Akt phosphorylation by 85 and 100%, respectively (Fig. 2,B–D).
Despite themagnitude of this effect, there was a relativelymod-
est inhibitory effect on each of the Akt substrates. There was no
significant effect of Akt1i alone on any of the substrates mea-
sured (Fig. 2,B and E–H). Akt2i alone, at the lowest dose, inhib-
ited insulin-dependent pThr-1462 TSC2, p-Ser9 GSK3, and
pThr-642 AS160 by 20–30%. A similar effect was seen for insu-
lin-stimulated GLUT4 translocation (Fig. 2I). The combined
effects of Akt1i andAkt2i at 10M eachwere not different from
that seen with 10 M Akt2i except in the case of pThr-1462
TSC2 where combined treatment resulted in a much more
potent inhibition. At higher drug concentrations we observed
substantial inhibition of Akt substrate phosphorylation and
GLUT4 translocation either with Akt2i alone or with both in
combination. For example, at 50 M when both drugs were
added simultaneously there was almost complete inhibition of
pThr-642 AS160, pThr-1462 TSC2, and GLUT4 translocation.
This indicates that the inability of the drugs to inhibit these
processes at lower doses (10 M) is not likely due to the activity
of an alternate kinase. Looking at the effects of the isoform-
specific inhibitors alone, it was clear that Akt1i had little effect
on substrate phosphorylation or on GLUT4 translocation at
any dose tested. This suggests that even at the highest dose
FIGURE 1. Rapamycin potentiates insulin- and PDGF-stimulated Akt
phosphorylation but has no effect on downstream substrates. Differen-
tiated 3T3-L1 adipocytes or PDGF receptor-expressing 3T3-L1 adipocytes
were serum-starved in Krebs-Ringer phosphate buffer for 2 h in the presence
or absence of 20 nM rapamycin and stimulated with insulin (200 nM) or PDGF
(20 ng/ml) for the indicated time. A, total cell lysates immunoblotted with
antibodies as described. B and C, quantification of immunoblots. D, GLUT4
translocation measured as described. E, integrated area under the curves
(AUC) of B and C, respectively. Error bars indicate S.E. of three independent
experiments. *, p 0.05;**, p 0.01; and ***, p 0.001.
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where there is some cross-reactivity of Akt1i with Akt2 (Fig.
2A), there still must be sufficient residual Akt2 activity to sus-
tain normal biological function. This is consistent with previ-
ous studies showing a dominant role for the Akt2 isoform in
metabolic regulation (30). Despite this, redundancy between
Akt1 and Akt2 in terms of most of the downstream actions was
evident. Thiswasmost clearly evident for the effects of Akt2i on
AS160 phosphorylation. At 50 M, a dose that almost com-
pletely blocked Akt2 activation (Fig. 2, C and D), Akt2i alone
had a modest inhibitory effect (42%) on AS160 phosphoryla-
tion, and there was no further inhibition even at higher concen-
trations of the drug (Fig. 2F). However, when Akt2i was com-
bined with Akt1i, even at 50 M, almost complete inhibition of
AS160 phosphorylation was evident. AS160 plays an important
role in insulin-regulated GLUT4 translocation (31). Based on
the present data it seems possible that AS160 may not be the
sole determinant of the insulin effect on this process because at
50–100 M concentrations of Akt2i we observed40% inhibi-
tion of AS160 phosphorylation at Thr-642 whereas insulin-
stimulatedGLUT4 translocationwas inhibited by60%.Alter-
natively, as is the case for Akt, there may also be nonlinearity
further down the pathway in which case even modest reduc-
tions in AS160 phosphorylation may cause a larger effect on
GLUT4 translocation due to the intrinsic threshold at this
node.
To confirm these observations using pharmacological inhib-
itors we used Akt2-specific siRNAs to reduce Akt2 expression
in adipocytes (supplemental Fig. S2). Again, a robust reduc-
tion in the levels of Akt2 was accompanied by only a modest
change in insulin-stimulated phosphorylation of AS160 and S6
(supplemental Fig. S2) and very little if any change in insulin-
stimulated GLUT4 translocation (supplemental Fig. S2). These
data are consistent with previous reports where reduced Akt2
did not result in similar reductions in downstream insulin
actions (30, 32, 33) and the data obtained using the Akt
inhibitors.
Minimal Akt Is Sufficient for Downstream Signaling and
GLUT4 Translocation—One explanation for the discrepancy
between Akt phosphorylation and activity is that, in the cell
minimal activation ofAkt is required to elicit a robust biological
effect. To test this we combined data from all of the studies
reported here and examined the relationship between Akt
phosphorylation and the other variables (Fig. 3). The relation-
ship between Akt phosphorylation, at both Thr-308 and Ser-
473, with GLUT4 translocation, AS160 phosphorylation, GSK3
phosphorylation, andTSC2 phosphorylationwas similar, yield-
ing a sigmoidal dose-response curve (Fig. 3,A and B). The ED50
for each of these variables was 0.05–0.22 (Fig. 3C). In contrast,
AS160 phosphorylation and GLUT4 translocation showed a
linear relationship using identical analyses (Fig. 3D). This indi-
cates that there is a nonlinear relationship in the absolute level
of signal in upstream elements of the pathway. This makes it
FIGURE2.Acute inhibitionofAktusingisoform-specificAkt inhibitors.3T3-L1adipocyteswereserum-starved inKrebs-Ringerphosphatebuffer for2h.Cellswere
treatedwith either 0.1%dimethyl sulfoxide (DMSO) or the indicated dose of Akt1i and/or Akt2i or wortmannin (100 nM,Wort) for 30min prior to exposure to 100 nM
insulin for 20min. A, total cell lysates were immunoprecipitated (IP) using Akt1 or Akt2 isoform-specific antibodies and immunoblottedwith pThr-308 Akt, pSer-473
Akt, Akt1, or Akt2 antibodies. B, total cell lysates were immunoblotted with pThr-308 Akt, pSer-473 Akt, total Akt, pSer-588 AS160, pThr-642 AS160, Total AS160,
pThr-1462TSC2, total TSC2,pSer-21/9GSK3/,rGSK3antibodies.C–H, immunoblotswerequantified. I,HA-GLUT4translocationwasmeasuredasdescribed.Error
bars indicate S.E. of three independent experiments. *, p 0.05; **, p 0.01; and ***, p 0.001 comparedwith insulin control.
FIGURE 3. Minimal activation of Akt is required for downstream insulin
action. Data from Figs. 1 and 2 were normalized to the level of either (A)
Thr-308 or (B) Ser-473 Akt phosphorylation that was obtained when 3T3-L1
adipocytes were stimulated with insulin (100 nM) for 20 min. GLUT4 translo-
cation to the PM, pThr-642 AS160, pSer-21/9 GSK3/, and pThr-1462 TSC2
was plotted against pThr-308 Akt or pSer-473 Akt on a normal scale and log
scale (inset). Each data point represents the mean of three independent
experiments. C, half-maximal dose (ED50) derived from fitting of the data in A
as described under “Experimental Procedures.” Error bars indicate S.E.D, rela-
tionship between GLUT4 translocation and AS160 phosphorylation calcu-
lated under identical conditions as a control.
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unlikely that changes in the level of Akt phosphorylationwithin
the upper range of its activity curve (0.3) will have any signif-
icant biological outcome.
In Silico Simulation of Akt Activity and Protein Level on
GLUT4 Translocation—We next attempted to simulate these
findings using a computationalmodel of theAkt signaling path-
way, termed the Virtual Adipocyte Platform. This platformwas
built,modeled, and validated using previously published data of
various signaling events and biological outcomes such as
GLUT4 translocation. Initially, the model was unable to repli-
cate the experimental data because themodel assumed that Akt
associates with the plasma membrane with an affinity of 1 M
(Fig. 4A). By increasing the binding affinity of Akt to the PM
from 1 M to 15 nM, approximating the binding affinity of Akt
to PI(3,4,5)3P (34), the model yielded a good fit of the data
whereby10%ofAkt2 activitywas sufficient tomediate almost
100% of insulin-stimulated GLUT4 translocation to the PM
(Fig. 4B).
Insulin-stimulated Protein Synthesis Displays Nonlinear
Relationship with Akt Activity—We next wanted to establish
whether alternate Akt-dependent actions of insulin displayed
similar nonlinear behavior. Protein synthesis is also stimulated
by insulin, and this is Akt-dependent (35) (supplemental Fig.
S3), and its regulation occurs independently of increased glu-
cose transport. The dose-response curve for insulin-stimulated
protein synthesis was shifted further to the left compared with
GLUT4 translocation, and so maximal activation of protein
synthesis was achieved by activation of as little as 2% of the
entire Akt pool (Fig. 5, A and B). Phosphorylation of PRAS40, a
regulator of mTORC1 and protein synthesis (36, 37), was less
sensitive to insulin compared with protein synthesis per se (Fig.
5A). These data indicate that the nonlinearity within the insulin
signaling pathway is not constrained to GLUT4 translocation.
Nonlinearity at PM—Wehave shown previously that there is
better agreement in the absolute level ofAkt phosphorylation at
the PM and substrate phosphorylation (28), suggesting that
spatial regulation may play a role. To examine this more quan-
titatively we performed further analyses on the PM fraction
isolated from adipocytes. Consistent with our previous studies
(28), there was a better correlation between Akt phosphoryla-
tion and substrate phosphorylation at the PM,with the ED50 for
insulin-stimulated pSer-473 Akt at the PM being somewhat
lower than that observed in the whole cell lysate (Fig. 6, A and
B). However, this was inadequate to account for the entire dis-
crepancy, and the relationship between phosphorylation of Akt
at the PM and its substrates remained sigmoidal (Fig. 6B),
requiring 19–23% PM Akt phosphorylation for half-maximal
substrate phosphorylation (Fig. 6E). Interestingly, AS160 phos-
phorylation at the PMwasmore sensitive than in the whole cell
lysate, raising the possibility that AS160 plays an important
functional role at this location (28). To confirm the nonlinearity
between PM-localized Akt phosphorylation and its substrates,
FIGURE 4. Reduction of Akt protein or phosphorylation level using the Virtual Adipocyte Platform. A, in silico effect of reducing the protein level (black,
square) or activity (gray, diamond) of Akt1, Akt2, or Akt1 and Akt2 on insulin-stimulated GLUT4 translocation to the PM using Akt binding affinity to PI(3,4,5)P3
of 1M. B, in silico effect of reducing Akt1, Akt2, or Akt1 and Akt2 on insulin-stimulated GLUT4 translocation to the PM using Akt binding affinity to PI(3,4,5)P3
of 15 nM.
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we analyzed previous data using the rapalog dimerization sys-
tem (ARIAD) to recruit Akt selectively to the PM for activation
(38). The total cell lysate analysis of these experiments repre-
sented PMAkt, and consistent with the PM fractionation data,
very low levels of rapalog-induced Akt were required for half-
maximal substrate phosphorylation (4–9%) (Fig. 6, D and E).
Akt Substrates Respond to Changes in Rate of Akt Activa-
tion—Most of the studies described above have involved mea-
suring the change in the absolute level of phosphorylation at a
specific time point. We next wanted to examine the possibility
that Akt substratesmay better respond to changes in the rate of
Akt phosphorylation. By examining the time course of phos-
phorylation at two separate insulin doses we made the follow-
ing observations. First, overall there was a strong correlation
between the initial rate of change in phosphorylation in all
parameters measured (Fig. 7, A and B). Second, there was a
dose-dependent increase in the initial rate of phosphorylation
for Akt, AS160, PRAS40, andGSK3 but not for FoxO1 (Fig. 7,A
andB). These data highlight the rate of changeofAkt phosphor-
ylation as a key parameter in signal transmission. When dose-
and time-dependent phosphorylation were plotted together in
a three-dimensional surface chart, it was obvious that the three-
dimensional surface of p473Akt differed from both pAS160 as
well as pFoxO1 (Fig. 7C), further emphasizing the demultiplex-
ing capacity at the level of Akt.
DISCUSSION
Akt is a major regulatory node for many essential biological
processes. A number of feedback intermediates have been
described that modulate Akt signaling (9, 12, 39).We have pre-
viously found that a relatively small amount of Akt phosphory-
lation is required to elicit robust outputs (27, 28, 40). Hence,
changes in Akt phosphorylation do not translate into equiva-
lent changes downstream. In the current study we provide evi-
dence that Akt displays switch-like and/or sensitivity amplifi-
cation behavior. Moreover, there is heterogeneity in the
engagement of Akt with its different substrates in terms of dose
and kinetic behavior, raising the possibility of demultiplexing
within the pathway.
A range of possibilities could explain the relationship
between Akt and its downstream substrates. This includes spa-
tial regulation of components in the pathway or the existence of
feedback or feedforward loops as has been documented for
other signaling systems (41). We have attempted to interrogate
the role of spatial regulation in the present studies, and
although there did seem to be a closer correspondence between
Akt and substrate phosphorylation at the PM this was still
insufficient to explain the lack of concordance between Akt
phosphorylation and that of its substrates. The PM is a hetero-
geneous organelle, however being comprised of raft and non-
raft domains. It has also been proposed thatAS160 is phosphor-
ylated when attached to intracellular GLUT4 vesicles (21, 31).
Therefore, a more rigorous analysis of the subcellular distribu-
tion of the components in the insulin signaling pathway needs
to be undertaken to determine the contribution of spatial reg-
ulation to the quantitative relationship between each of the
components in the pathway.
Experimental investigation of feedback pathways in signal
transduction is complicated. A limitation of the present studies
is that all studieswere performedon cell populations, and so the
outputs potentially represent the average of many different
responses in individual cells. Regardless, a notable feature of the
outputs measured is that in the adipocyte there was little evi-
dence for adaptive behavior as would be the case if the pathway
were dominated by negative feedback loops. For instance, the
insulin addition was accompanied by a rapid rise to a new
steady state, and this was maintained as long as insulin was
present in the medium. There was evidence for attenuation of
Akt308 phosphorylation at low insulin doses (Fig. 7A), but this
did not translate into changes downstream in the pathway.
One notable feature was the switch like behavior at Akt. The
relationship betweenAkt phosphorylation and all other param-
eters measured was sigmoidal with a steep response at around
the physiological insulin concentration whereas the relation-
FIGURE 5. Insulin-mediated protein synthesis displayed a nonlinear rela-
tionship with Akt phosphorylation. 3T3-L1 adipocytes were stimulated
with the indicated dose of insulin, and [3H]leucine incorporation into protein
was measured as described under “Experimental Procedures.” Whole cell
lysate was immunoblotted with antibodies specific for pThr-308 Akt, pSer-
473 Akt, total Akt, pThr-246 PRAS40, and total PRAS40. A, insulin dose-re-
sponse curve of protein synthesis and pThr-246 PRAS40 phosphorylation.
B, phosphorylation dose-response curves of pThr-308 Akt or pSer-473 Akt
with protein synthesis or pPRAS40. C, ED50 (pThr-308 Akt dose and pSer-473
Akt dose) derived from fitting of the data. Error bars indicate S.E. from three
independent experiments.
Plasticity in Akt Signaling
FEBRUARY 24, 2012•VOLUME 287•NUMBER 9 JOURNAL OF BIOLOGICAL CHEMISTRY 6135
ship between Akt substrate AS160, and its presumed end point
GLUT4 translocation was linear. As noted by Koshland et al.
(42) sigmoidal behavior is characteristic of sensitivity amplifi-
cation steps. In this case a 10% change in the input (Akt phos-
phorylation) gives rise to a 50% change in the output (see Fig. 3).
This indicates that Akt is highly sensitive, providing the basis
for amplification. This behavior is intriguing because contrary
to early expectations there is little evidence for amplification in
proximal elements of the pathway, and so Akt may represent
one of the major amplification steps in the pathway.
It is well established that mTOR forms part of a negative
feedback loop within the insulin signaling pathway, and multi-
ple targets including IRS1 and Rictor have been suggested
(8–12, 39). Our studies show that this loop exists in adipocytes
but that IRS1 may not be the major target of feedback regula-
tion. Our data are consistent with the recently described inhib-
itory effect ofmTOR/S6K onRictor, a subunit ofmTORC2 that
phosphorylates Akt on Ser-473 (12). Another feature of the
feedback loop is that it does not appear to have a major impact
on signaling under conditions of robust activation. This is not
surprising as small amplitude negative feedback loops probably
play a more important role in stabilizing signaling under basal
conditions (41). It is conceivable then that the mTOR negative
feedback loop combined with the amplification step at Akt play
a key role in filtering out noise that might influence the system
under nonstimulated conditions. It is likely that we have over-
looked the impact of this parameter in the present study
because we have used an artificial basal condition of zero insu-
lin. In vivo, the basal condition varies throughout the day, par-
ticularly because insulin is secreted in an oscillatory manner
with a period of 10–15 min (43) even under fasting conditions.
We also noted a lack of concordance in behavior of compo-
nents downstream of Akt. For example, FoxO1 phosphoryla-
tion was more sensitive to insulin, shown by its low ED50 for
pAkt, than the phosphorylation of other substrates (Fig. 3C),
whereas protein synthesis was more sensitive than GLUT4
translocation (Figs. 3C and 5C). This suggests that the input
signal, in this case insulin, can be split into multiple discrete
outputs as the signal filters down the pathway. This demulti-
plexing characteristic is potentially important as it raises the
possibility that it might be possible to target specific outputs
without perturbing the activity of others. So in the context of a
cancer cell it would be desirable to design a drug to cancel out
the antiapoptotic function of Akt while preserving other activ-
ities of the pathway.
A technical implication of these studies is that caution should
be taken in equating levels of Akt phosphorylation with Akt
FIGURE 6. Phosphorylation of Akt at the PM is more sensitive to insulin
but is still disconnected fromAkt substrate phosphorylation. A, differen-
tiated 3T3-L1 adipocytes stimulated for 30 min with the indicated dose of
insulin. Subsequently, the PM fractionwas isolated, and both PM fraction and
whole cell lysate (WCL) were immunoblotted with antibodies specific for
pSer-473 Akt, total Akt, pThr-642 AS160, total AS160, pSer-21/9 GSK3/,
total GSK3, tubulin, and 14-3-3. B, quantification of immunoblots in A. ED50
(insulin dose)was derived from fitting of the data. Error bars indicate S.E. from
three independent experiments.C, phosphorylation dose-response curves of
pSer-473 Akt with pThr-642 AS160 and pSer-9 GSK3 in the whole cell lysate
or at the PM. D, quantification of rapalog-induced Akt data published in Ref.
38. E, ED50 (pSer-473Akt dose) derived from fittingof thedata inC andD. Error
bars indicate S.E.
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activity particularly at the higher end of the response range. It is
clear from these studies that the PI3K/Akt pathway displays a
similar degree of complexity to other signaling pathways (44).
This comprises sensitization amplification, demultiplexing
capacity, and positive and negative feedback. This is likely
encoded by a combination of covalent and allosteric regulatory
mechanisms.Although our studies have focused on the forward
reactions in the pathway, the opposing reactions regulated by
phosphatases are likely to be equally important. Finally, because
Akt substrates are found in discrete cellular locations, spatial
aspects also must not be overlooked.
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